Fosfomycin: Pharmacological, Clinical and Future Perspectives.

about

Community-Acquired Urinary Tract Infection by in the Era of Antibiotic Resistance Conserved collateral antibiotic susceptibility networks in diverse clinical strains of Escherichia coli Swine Enteric Colibacillosis in Spain: Pathogenic Potential of ST10 and ST131 Isolates

P2860

Q57821217-BF82021F-3859-462E-8215-0F93FE9E82C6 Q58756032-25A33F89-6429-4949-8340-343A14EC295D Q59136944-08DF50EA-5344-4373-BDE6-03A5296EDAC5

P2860

Fosfomycin: Pharmacological, Clinical and Future Perspectives.

Item

http://www.wikidata.org/entity/Q47136072

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Fosfomycin: Pharmacological, Clinical and Future Perspectives.

@en

Fosfomycin: Pharmacological, Clinical and Future Perspectives.

@nl

type

Item

label

Fosfomycin: Pharmacological, Clinical and Future Perspectives.

@en

Fosfomycin: Pharmacological, Clinical and Future Perspectives.

@nl

prefLabel

Fosfomycin: Pharmacological, Clinical and Future Perspectives.

@en

Fosfomycin: Pharmacological, Clinical and Future Perspectives.

@nl

P1476

Fosfomycin: Pharmacological, Clinical and Future Perspectives

@en

P2093

Anneke Corinne Dijkmans

http://www.w3.org/2001/XMLSchema#string

Cees van Nieuwkoop

http://www.w3.org/2001/XMLSchema#string

Erik Bert Wilms

http://www.w3.org/2001/XMLSchema#string

Ingrid Maria Catharina Kamerling

http://www.w3.org/2001/XMLSchema#string

Jacobus Burggraaf

http://www.w3.org/2001/XMLSchema#string

Johan Willem Mouton

http://www.w3.org/2001/XMLSchema#string

Natalia Veneranda Ortiz Zacarías

http://www.w3.org/2001/XMLSchema#string

P2860

MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli

Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance

Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE

Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coli.

Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.

Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26

Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis.

P31

scholarly article

P356

10.3390/ANTIBIOTICS6040024

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jasper Stevens

Cees van Nieuwkoop

Jasper Stevens

P577

2017-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29088073

http://www.w3.org/2001/XMLSchema#string

P932

5745467

http://www.w3.org/2001/XMLSchema#string

Fosfomycin: Pharmacological, Clinical and Future Perspectives.

about

P2860

P2860

Fosfomycin: Pharmacological, Clinical and Future Perspectives.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P932